transform="translate(188.000000, 15.000000)"

P.D. Soros Fellowship for New Americans

Share 0

Vivek Ramaswamy, 2011

JD, Yale University

Vivek Ramaswamy is the child of immigrants from India

Fellowship awarded to support work towards a JD in Law at Yale University

VIVEK RAMASWAMY is the founder and CEO of Axovant Sciences. 

Vivek was born in Cincinnati to Indian parents. In high school he was class valedictorian, a nationally ranked junior tennis player and an accomplished pianist.

Vivek graduated from Harvard College in 2007, summa cum laude and Phi Beta Kappa with a major in biology. Later he entered Yale Law School.

While at Harvard, a precis of his senior thesis, on the ethical questions raised by creating human-animal chimeras was published in the Boston Globe and The New York Times. He was chairman of the Harvard Political Union and served as one of three undergraduates chosen for an advisory board for the selection of the current president of Harvard. During his senior year, Vivek co-founded StudentBusinesses.com, a technology startup company which connected entrepreneurs with professional resources via the internet, and he led the company to its acquisition in 2009.

After Harvard college, Vivek worked for three years in life sciences investing in New York before pursuing his law degree. 

Education
  • JD Law | Yale University 2013
  • AB Biology | Harvard University 2007
Work History
  • Axovant Sciences, Founder and CEO
Related Articles
10.09.17

Aris Baras and Vivek Ramaswamy Make The List: Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine

Read More
09.13.17

The New American 2017-2018: Our Alumni Magazine

Read More
04.03.17
Rebecca Beyer

Pursuing the Potential of Abandoned Pharmaceuticals

Two Paul & Daisy Soros Fellows are behind the largest biotech IPO in history—Vivek Ramaswamy (2011 Fellow), the founder and CEO of Roivant Sciences, and Pavan Cheruvu (2004 Fellow), the chief of staff at Roivant Sciences.

Read More
03.15.17

How Vivek Ramaswamy's Roivant Sciences Stays Innovative

Read More